| REGISTERED NUMBER: |
| Unaudited Financial Statements |
| for the Year Ended 31 January 2025 |
| for |
| HEALTHPHARM LTD |
| REGISTERED NUMBER: |
| Unaudited Financial Statements |
| for the Year Ended 31 January 2025 |
| for |
| HEALTHPHARM LTD |
| HEALTHPHARM LTD (REGISTERED NUMBER: 09602276) |
| Contents of the Financial Statements |
| for the Year Ended 31 January 2025 |
| Page |
| Company Information | 1 |
| Balance Sheet | 2 |
| Notes to the Financial Statements | 3 |
| HEALTHPHARM LTD |
| Company Information |
| for the Year Ended 31 January 2025 |
| Director: |
| Secretary: |
| Registered office: |
| Registered number: |
| Accountants: |
| Accountants |
| Northern Assurance Buildings |
| 9-21 Princess Street |
| Manchester |
| M2 4DN |
| HEALTHPHARM LTD (REGISTERED NUMBER: 09602276) |
| Balance Sheet |
| 31 January 2025 |
| 2025 | 2024 |
| Notes | £ | £ | £ | £ |
| Fixed assets |
| Tangible assets | 5 |
| Investments | 6 |
| Investment property | 7 |
| Current assets |
| Debtors | 8 |
| Cash at bank |
| Creditors |
| Amounts falling due within one year | 9 |
| Net current assets |
| Total assets less current liabilities |
| Capital and reserves |
| Called up share capital | 10 |
| Retained earnings |
| Shareholders' funds |
| The director acknowledges his responsibilities for: |
| (a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
| (b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company. |
| The financial statements were approved by the director and authorised for issue on |
| HEALTHPHARM LTD (REGISTERED NUMBER: 09602276) |
| Notes to the Financial Statements |
| for the Year Ended 31 January 2025 |
| 1. | Statutory information |
| Healthpharm Ltd is a |
| 2. | Statement of compliance |
| 3. | Accounting policies |
| Basis of preparing the financial statements |
| Preparation of consolidated financial statements |
| The financial statements contain information about Healthpharm Ltd as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements. |
| Tangible fixed assets |
| Fixtures and fittings -15% straight line |
| Tangible fixed assets are stated at cost (or deemed cost) or valuation less accumulated depreciation and accumulated impairment losses. |
| Investment property |
| Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss. |
| Taxation |
| Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
| Current or deferred taxation assets and liabilities are not discounted. |
| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
| Deferred tax |
| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. |
| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
| Debtors and creditors receivable / payable within one year |
| Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the Profit and Loss Account in administrative expenses. |
| HEALTHPHARM LTD (REGISTERED NUMBER: 09602276) |
| Notes to the Financial Statements - continued |
| for the Year Ended 31 January 2025 |
| 3. | Accounting policies - continued |
| Fixed asset investments |
| Interests in subsidiaries, associates and jointly controlled entities are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Transaction costs are expensed to profit or loss as incurred. Changes in fair value are recognised in other comprehensive income except to the extent that a gain reverses a loss previously recognised in profit or loss, or a loss exceeds the accumulated gains recognised in equity; such gains and loss are recognised in profit or loss. |
| A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities. |
| An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a longer-term interest and where the company has a significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate. |
| Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities. |
| 4. | Employees and directors |
| The average number of employees during the year was |
| 5. | Tangible fixed assets |
| Fixtures |
| and |
| fittings |
| £ |
| Cost |
| At 1 February 2024 |
| and 31 January 2025 |
| Depreciation |
| At 1 February 2024 |
| Charge for year |
| At 31 January 2025 |
| Net book value |
| At 31 January 2025 |
| At 31 January 2024 |
| 6. | Fixed asset investments |
| Other |
| investments |
| £ |
| Cost |
| At 1 February 2024 |
| and 31 January 2025 |
| Net book value |
| At 31 January 2025 |
| At 31 January 2024 |
| HEALTHPHARM LTD (REGISTERED NUMBER: 09602276) |
| Notes to the Financial Statements - continued |
| for the Year Ended 31 January 2025 |
| 7. | Investment property |
| Total |
| £ |
| Fair value |
| At 1 February 2024 |
| and 31 January 2025 |
| Net book value |
| At 31 January 2025 |
| At 31 January 2024 |
| 8. | Debtors: amounts falling due within one year |
| 2025 | 2024 |
| £ | £ |
| Trade debtors |
| Amounts owed by group undertakings |
| Other debtors |
| 9. | Creditors: amounts falling due within one year |
| 2025 | 2024 |
| £ | £ |
| Trade creditors |
| Corporation tax |
| VAT | 2,222 | - |
| Accruals and deferred income |
| 10. | Called up share capital |
| Allotted, issued and fully paid: |
| Number: | Class: | Nominal | 2025 | 2024 |
| value: | £ | £ |
| Ordinary | £1 | 1 | 1 |
| 11. | Director's advances, credits and guarantees |
| The following advances and credits to a director subsisted during the years ended 31 January 2025 and 31 January 2024: |
| 2025 | 2024 |
| £ | £ |
| Balance outstanding at start of year | ( |
) |
| Amounts advanced |
| Amounts repaid | ( |
) | ( |
) |
| Amounts written off | - | - |
| Amounts waived | - | - |
| Balance outstanding at end of year |
| There is interest payable on the amount outstanding. |